EUVIMEDEUVIMED entdecken
Crossref

Combination therapy with mepolizumab and dupilumab in a patient with severe uncontrolled chronic rhinosinusitis with nasal polyps in the context of eosinophilic granulomatosis with polyangiitis

Philine von Spiegel, Christian Betz, Benjamin Becker, Anna Sophie Hoffmann

Laryngo-Rhino-Otologie · 01.05.2024 · 103 (S 02 S 02) · S324

DOI: 10.1055/s-0044-1785100 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Laryngo-Rhino-Otologie, erschienen am 01.05.2024. Verfasst von Philine von Spiegel und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Monoclonal antibodies (biologics) are increasingly used in the treatment of severe uncontrolled forms of chronic rhinosinusitis with nasal polyps. In some patients with comorbidities, a combination therapy of biologics needs to be discussed and can be useful as an individual therapy concept. Material and methods Case report of a patient from the biologics consultation hour at the University Hospital Hamburg-Eppendorf.

Results

The 33-year old patient was diagnosed with eosinophilic granulomatosis with polyangiitis in 2015. In the course of the disease the patient displayed purpura as well as pulmonary, cardiac and transient neurological symptoms with tissue and peripheral eosinophilia. Therapy was initiated with azathioprine (50 mg/d) and mepolizumab (100 mg/every 4 weeks). In 2021, a pansinus surgery was performed for the treatment of chronic rhinosinusitis with nasal polyps. Due to pulmonary decompensation, the dose of mepolizumab (300 mg/every 4 weeks) was increased in February 2023. In the clinical examination, the patient further presented an NPS of 6 and anosmia. The SNOT-22 was 52. Our interdisciplinary Board of Allergy and Immunology therefore recommended the additional administration of dupilumab every 2 weeks. The combination therapy of mepolizumab and dupilumab showed a significant reduction in SNOT-22 and an increase in olfactory ability. To date there have been no significant side effects.

Discussion

The case report shows the effectiveness and tolerability of the combination of these two biologics for severe forms of chronic rhinosinusitis with nasal polyps. The indication should be provided after interdisciplinary expert discussion and reevaluated regularly. Furthermore, all cases should be collected for future treatment recommendations. Publication History Article published online: 19 April 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Zitieren

APA

Spiegel, P. V., Betz, C., Becker, B., & Hoffmann, A. S. (2024). Combination therapy with mepolizumab and dupilumab in a patient with severe uncontrolled chronic rhinosinusitis with nasal polyps in the context of eosinophilic granulomatosis with polyangiitis. Laryngo-Rhino-Otologie, 103(S 02 S 02), S324. https://doi.org/10.1055/s-0044-1785100

Vancouver

Spiegel PV, Betz C, Becker B, Hoffmann AS. Combination therapy with mepolizumab and dupilumab in a patient with severe uncontrolled chronic rhinosinusitis with nasal polyps in the context of eosinophilic granulomatosis with polyangiitis. Laryngo-Rhino-Otologie. 2024;103(S 02 S 02):S324. doi:10.1055/s-0044-1785100

BibTeX
@article{Spiegel2024,
  author = {Spiegel, Philine von and Betz, Christian and Becker, Benjamin and Hoffmann, Anna Sophie},
  title = {Combination therapy with mepolizumab and dupilumab in a patient with severe uncontrolled chronic rhinosinusitis with nasal polyps in the context of eosinophilic granulomatosis with polyangiitis},
  journal = {Laryngo-Rhino-Otologie},
  year = {2024},
  volume = {103},
  number = {S 02 S 02},
  pages = {S324},
  doi = {10.1055/s-0044-1785100}
}
Kostenlos starten →